Celldex Therapeutics, Inc. (CLDX)
-NasdaqGS 12.69 
0.29(2.34%) 18 May 04:00 SGT|After Hours
:
12.40 0.29 (2.29%) 18 May 04:35 SGT
| Prev Close: | 12.40 |
|---|
| Open: | 12.37 |
|---|
| Bid: | 11.34 x 300 |
|---|
| Ask: | 12.69 x 300 |
|---|
| 1y Target Est: | 15.75 |
|---|
| Beta: | 2.87 |
|---|
| Next Earnings Date: | 5-Aug-13 |
|---|
| Day's Range: | 12.13 - 12.75 |
|---|
| 52wk Range: | 3.91 - 14.09 |
|---|
| Volume: | 850,594 |
|---|
| Avg Vol (3m): | 1,821,500 |
|---|
| Market Cap: | 1.03B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.99 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Celldex Therapeutics' Management Presents at Credit Suisse Antibody Day Conference (Transcript)at Seeking Alpha(Sun, 12 May)
- CELLDEX THERAPEUTICS, INC. FinancialsEDGAR Online Financials(Sat, 11 May)
- Celldex Therapeutics Announces Upcoming Presentation at the Credit Suisse 2013 Antibody DayGlobeNewswire(Mon, 6 May)
- Predicting Biotech Stock Moves Using Top Consensus Picks By Legendary Fund Managersat Seeking Alpha(Mon, 6 May)
- Investors Ride 5 Earnings Rollercoaster Ridesat Wall St. Cheat Sheet(Sun, 5 May)
- CELLDEX THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Fri, 3 May)
- Celldex Therapeutics Earnings: Here’s Why Investors are Happy Nowat Wall St. Cheat Sheet(Thu, 2 May)
- Celldex Reports First Quarter 2013 Financial ResultsGlobeNewswire(Thu, 2 May)
- CELLDEX THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements anEDGAR Online(Thu, 2 May)
- These 3 Biotech Stocks Look Interestingat Motley Fool(Tue, 30 Apr)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 89.67 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.95 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.22 |
|---|
| Mean Recommendation*: | 1.3 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of novel therapeutics for human health care primarily in the United States.
View More